Based on the overall results received from the studies till now, the company has concluded that the properties of the lead molecule would not outperform the already commercialized COMT inhibitors.
Timo Lappalainen, president and CEO, said: “Based on the achieved results it is unlikely that we would succeed in meeting the original goal and the primary purpose of this project, that is to develop this molecule into a medicine that would provide considerable added value to patients suffering from Parkinson’s disease.”